Haleon PLC

Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

Haleon Pakistan plans to start manufacturing multivitamin brand Centrum in the country for domestic sales and export, its CEO said, as it seeks to boost sales in the country amid lower inflation.

Haleon Pakistan to manufacture Centrum multivitamins

Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3.

Haleon: Guidance Implies Uncertainty Around Flu Season

WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024.

Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation

BHP Billiton

Canadian Imperial Bank of Commerce

Eastman Chemical

Medtronic

MDU Resources Group

Philip Morris

Starbucks

Visa

Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, such as MDU Resources and Haleon.

Dividend Income: Lanny's October 2024 Summary

Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy

Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising

Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.

Haleon plc (HLN) Q3 2024 Sales Call Transcript

Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.

Panadol maker Haleon takes hit from currency headwinds

Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.

Haleon reports marginal decline in third-quarter revenue

Haleon (HLN) share price has retreated in the past few weeks, erasing some of the gains made earlier this year. Its London stock dropped to 375p, its lowest point since August 29, while its American ADR fell to $9.90, down by 7% from its highest level this year.

Is the Haleon share price in trouble ahead of earnings?

Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.

Haleon gets target hike as UBS raises 'forever' sales target

Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.

Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway

Insulet

Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors?

HLN or PODD: Which Is the Better Value Stock Right Now?

Pfizer

UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.

Haleon's buy rating restated after Pfizer cuts down stake

Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker.  The FTSE 100 consumer health group said made the purchase at a price of 308p per share.

Haleon buys back some shares as Pfizer sells down stake

Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.

Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon

Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.

Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner

British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.

Sensodyne maker Haleon to raise stake in China JV

Apple

adidas AG

Colgate-Palmolive

AB Electrolux

Expedia

Alphabet

iShares U.S. Treasury Bond ETF

Interactive Brokers

Legal & General Group PLC

London Stock Exchange Group PLC

Mowi ASA

Microsoft

Charles Schwab

Under Armour

UBS Group AG

Unilever

In this article, I go through a typical day and note 20 stocks whose revenue I contribute to, and would find it difficult not to. One motivation was to see how much of my budget at attention go into Magnificent 7 stocks, and whether that is in proportion to market cap. This list could be used to create a portfolio of 20 "counter-consumption" stocks with the goal of generating dividends to fund daily consumption.

20 'Every Day Stocks' I'd Struggle To Live Without

Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.

Haleon lays out pricing for £1bn bond offering

Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024 WARREN, N.J. , Sept. 3, 2024 /PRNewswire/ -- Eroxon® , the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.

Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription

Kellogg

As of Aug 9, 2024, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 2 Risk Off Stocks That May Implode In August

Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future.

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Reckitt Benckiser Group PLC

While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend.  Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.

Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off

Haleon PLC (LSE:HLN, NYSE:HLN) interim results showed its resilience and dependability in very tough markets, suggests Deutsche Bank adding it deserves a higher rating. “The stock has been strong into results and the positive margin performance, along with some low season improvement in respiratory sell-out, is supporting the stock.

Haleon a rare riser on tough day as Deutsche Bank hilts resilience

Haleon plc (NYSE:HLN ) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Bruno Monteyne - Bernstein Chris Pitcher - Redburn Atlantic David Hayes - Jefferies Rashad Kawan - Morgan Stanley Jeremy Fialko - HSBC Olivier Nicolai - Goldman Sachs Celine Pannuti - JPMorgan Iain Simpson - Barclays Operator Good morning, all. Thank you for joining us for the Haleon 2024 Half Year Results Q&A.

News for Haleon PLC Stock (HLN)